Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etigilimab +/- Nivolumab in Solid Tumors
NCT03119428Phase 1Terminated
- Sponsor
- OncoMed Pharmaceuticals
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of etigilimab in solid tumor (2 arms), sponsored by OncoMed Pharmaceuticals. Primary endpoints: Incidence of dose limiting toxicities at Day 29 and Incidence of treatment emergent adverse events at 2 years. Started May 2017; status: terminated.
02
Drugs
etigilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03119428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119428.